# JAZZ earnings call intelligence LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/JAZZ) · [Earnings tab](https://www.lopjlb.com/stock/JAZZ?tab=earnings) Updated: 2026-10-05T04:29:16 Quarters analyzed: 8 ## Cross-quarter narrative Across the nine earnings calls Jazz’s narrative shifted from a focus on temporary revenue dips and early‑stage trial timing to a broader emphasis on record revenue growth, expanding product launches and advancing late‑stage oncology assets. Early calls highlighted a dip in Rylaze revenue due to pediatric protocol shifts and regulatory uncertainty around zanidatamab and Epidiolex Japan. By Q4 2024 the company celebrated a $4 billion revenue milestone, Ziihera approval and continued strong demand across sleep, epilepsy and oncology, while noting trial‑readout delays. In 2025 the Chimerix acquisition and dordaviprone pipeline entered the spotlight, with mixed regulatory outlooks for zanidatamab, Zepzelca and dordaviprone. Q3 2025 introduced Modeyso launch and a top‑line zanidatamab readout, but also warned of upcoming generic competition for Xywav. The 2026 calls reflected a raised full‑year outlook driven by Xywav and oncology sales, yet underscored lingering regulatory risk for zanidatamab, potential generic erosion, and trial timing uncertainties for ACTION. Overall, the company moved from managing short‑term revenue volatility to positioning for sustained growth through product launches and late‑stage approvals, while regulatory and competitive risks remain persistent. ## Latest CallCard · Q2 Jazz Pharma posted record $1.21B Q2 revenue, 16% growth, raised full‑year guidance on strong Xywav and oncology sales, and highlighted upcoming zanidatamab approval and pipeline milestones. **Guidance:** raised — Full‑year revenue guidance lifted to $4.60‑$4.75B, driven by Xywav performance and oncology momentum. **Tone:** mgmt 0.8 · Q&A pressure 0.4 · divergence 0.4 Prepared remarks emphasized record revenue, growth momentum and confidence in upcoming zanidatamab launch, reflecting an optimistic outlook. ### Demand visibility Robust demand for Xywav and Epidiolex with strong patient adds. Xywav added ~525 net patients (200 narcolepsy, 325 IH) and Epidiolex saw 12% volume growth, both supported by field campaigns and digital outreach; generics remain limited. ### Margins / costs Margins pressured by royalty‑bearing products and higher SG&A/R&D spend. Non‑GAAP gross margin fell slightly due to Zepzelca and Modeyso royalties; SG&A and R&D rose 11% driven by Modeyso, zanidatamab trials and commercial capability investments. ### Capital allocation Continued disciplined investment in R&D, external collaborations and commercial capabilities. Capital deployed to AbCellera preclinical T‑cell engager deal, patient‑support programs, media spend for Xywav, Epidiolex capsule development, and pipeline trial funding. ### Milestones - **Zanidatamab PDUFA submission** [new]: PDUFA date set for Aug 25 2026; management confident of approval on or before that date. - **Zanidatamab NEJM publication** [delivered]: Phase III Horizon GEA 01 results published, supporting adoption. - **Zanidatamab interim OS analysis** [at_risk]: Second interim overall‑survival readout expected in 3Q 2026. - **Epidiolex capsule NDA** [new]: NDA submitted to FDA to broaden use of capsule formulation in approved indications. - **Phase III ACTION trial for Modeyso** [at_risk]: Interim overall‑survival analysis now anticipated in H1 2027. - **Xywav revenue guidance raise** [delivered]: Full‑year guidance lifted, citing double‑digit growth and slower generic uptake. - **Zepzelca label supplement to drop second‑line indication** [new]: Plan to submit labeling supplement in 3Q 2026 to remove second‑line use. - **AbCellera preclinical collaboration** [new]: Deal leverages T‑cell engager platform to discover novel multispecific antibodies. ### Fears / risks - **Regulatory**: Potential delay in zanidatamab approval despite management confidence. - **Generic competition**: High‑sodium oxybate generics could erode Xywav market share over time. - **Reimbursement**: Securing permanent J‑code and payer agreements for zanidatamab launch. - **Clinical trial timing**: ACTION trial interim analysis pushed to first half of 2027. - **Inventory**: No significant inventory issues for Epidiolex, but monitoring continues. - **FX impact**: Currency fluctuations boosted prior quarter results; reversal could affect growth. - **Market adoption**: Community physician uptake of zanidatamab may lag academic centers. - **Competitive landscape**: Emerging antiseizure therapies could challenge Epidiolex market share. ### Key quotes > “We delivered another outstanding quarter, generating record revenue of $1.2 billion representing 16% year-over-year growth.” — Renée Galá > “Xywav net product sales increased 13% to $471 million in the second quarter of 2026 compared to the second quarter of 2025.” > “Our non-GAAP adjusted gross margin declined slightly year-on-year, due to higher sales of Zepzelca and Modeyso, which carry third-party royalties.” > “Probably leading to even slower uptake of generics than we might have originally anticipated, which is leading to some of the raise we have for the guidance this year.” ## Quarter one-liners - **2026 Q2:** Jazz Pharma posted record $1.21B Q2 revenue, 16% growth, raised full‑year guidance on strong Xywav and oncology sales, and highlighted upcoming zanidatamab approval and pipeline milestones. - **2026 Q1:** JAZZ Q1'26: $1.1B revenue (+19% YoY), reaffirmed $4.25-4.5B FY guidance; Ziihera GEA PDUFA Aug 25, Modeyso $41M launch, Xywav 18% growth amid generic entry. - **2025 Q4:** — - **2025 Q3:** Jazz posted record $1.126 B Q3 revenue, secured FDA approvals for Modeyso and Zepzelca, saw double‑digit growth in Xywav and Epidiolex, and expects zanidatamab GEA readout later this quarter. - **2025 Q2:** Jazz reported $1.05B Q2 revenue, highlighted Xywav growth, announced upcoming FDA decisions for dordaviprone (Aug 18) and Zepzelca (Oct 7), and revised guidance lower end. - **2025 Q1:** Jazz Pharmaceuticals reported Q1 2025 revenue growth driven by Xywav and Epidiolex, highlighted progress on oncology pipeline and Chimerix acquisition, and reaffirmed its revenue guidance. - **2024 Q4:** Jazz reported record 2024 revenue over $4B, strong growth in sleep, epilepsy and oncology, met guidance, announced Ziihera approval and multiple pipeline milestones while noting some trial timing delays. - **2024 Q3:** Jazz Pharma reported strong Q3 growth driven by Xywav, Epidiolex and Zepzelca, while noting a temporary Rylaze revenue dip and advancing zanidatamab toward a November PDUFA deadline. ## Theme arcs - **Revenue growth** (improving): From $1.05B Q2 2025 to $1.21B Q2 2026 and raised FY guidance. - **Product demand** (stable): Consistently strong demand for Xywav, Epidiolex and oncology assets across calls. - **Regulatory risk** (deteriorating): Multiple pending approvals (zanidatamab, dordaviprone, Zepzelca) and at‑risk readouts. - **Competitive pressure** (new): Emergence of high‑sodium oxybate generics and Avadel patent issues in 2025‑2026. - **Margin pressure** (stable): Margins pressured by royalty‑bearing products and higher SG&A/R&D, but no major margin guidance shifts. - **Capital allocation** (stable): Continued disciplined investment in acquisitions, pipeline and commercial capabilities. - **Pipeline progression** (improving): Advancement of zanidatamab, Modeyso, ACTION and other late‑stage trials. ## Fear persistence - **Regulatory risk** [recurring]: Ongoing uncertainty around zanidatamab, dordaviprone, Zepzelca approvals. - **Competitive pressure** [recurring]: High‑sodium oxybate generics and Avadel patent challenges affecting Xywav and Rylaze. - **Pricing/reimbursement risk** [recurring]: Potential MFN Medicaid pricing changes and generic entry could pressure Xywav and Rylabe pricing. - **Inventory dynamics** [recurring]: Epidiolex growth moderated by prior‑year inventory build and seasonality. ## Guidance path 2024 Q3:maintained → 2024 Q4:maintained → 2025 Q1:maintained → 2025 Q2:lowered → 2025 Q3:maintained → 2025 Q4:vague → 2026 Q1:maintained → 2026 Q2:raised --- Research context only. Not personalized investment advice. API: `GET /bff/api/bigfive/earnings-intel/JAZZ`